149 related articles for article (PubMed ID: 19850021)
1. Serum levels of vascular endothelial growth factor and its receptors in patients with severe autism.
Emanuele E; Orsi P; Barale F; di Nemi SU; Bertona M; Politi P
Clin Biochem; 2010 Feb; 43(3):317-9. PubMed ID: 19850021
[TBL] [Abstract][Full Text] [Related]
2. Relationship between circulating vascular endothelial growth factor and its soluble receptors in adults with dengue virus infection: a case-control study.
Seet RC; Chow AW; Quek AM; Chan YH; Lim EC
Int J Infect Dis; 2009 Sep; 13(5):e248-53. PubMed ID: 19261502
[TBL] [Abstract][Full Text] [Related]
3. Circulating VEGF and its soluble receptors sVEGFR-1 and sVEGFR-2 in patients with acute leukemia.
Wierzbowska A; Robak T; Wrzesień-Kuś A; Krawczyńska A; Lech-Marańda E; Urbańska-Ryś H
Eur Cytokine Netw; 2003; 14(3):149-53. PubMed ID: 14656688
[TBL] [Abstract][Full Text] [Related]
4. Reduced serum vascular endothelial growth factor receptor-2 (sVEGFR-2) and sVEGFR-1 levels in gastric cancer patients.
Kikuchi S; Obata Y; Yagyu K; Lin Y; Nakajima T; Kobayashi O; Kikuichi M; Ushijima R; Kurosawa M; Ueda J
Cancer Sci; 2011 Apr; 102(4):866-9. PubMed ID: 21219538
[TBL] [Abstract][Full Text] [Related]
5. Associations of VEGF and its receptors sVEGFR-1 and -2 with cardiovascular disease and survival in prevalent haemodialysis patients.
Guo Q; Carrero JJ; Yu X; Bárány P; Qureshi AR; Eriksson M; Anderstam B; Chmielewski M; Heimbürger O; Stenvinkel P; Lindholm B; Axelsson J
Nephrol Dial Transplant; 2009 Nov; 24(11):3468-73. PubMed ID: 19561151
[TBL] [Abstract][Full Text] [Related]
6. Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of response.
Wong NS; Buckman RA; Clemons M; Verma S; Dent S; Trudeau ME; Roche K; Ebos J; Kerbel R; Deboer GE; Sutherland DJ; Emmenegger U; Slingerland J; Gardner S; Pritchard KI
J Clin Oncol; 2010 Feb; 28(5):723-30. PubMed ID: 20026801
[TBL] [Abstract][Full Text] [Related]
7. VEGF-A, VEGFR-1, VEGFR-2 and Tie2 levels in plasma of premature infants: relationship to retinopathy of prematurity.
Pieh C; Agostini H; Buschbeck C; Krüger M; Schulte-Mönting J; Zirrgiebel U; Drevs J; Lagrèze WA
Br J Ophthalmol; 2008 May; 92(5):689-93. PubMed ID: 18408080
[TBL] [Abstract][Full Text] [Related]
8. The effects of neoadjuvant anastrozole and tamoxifen on circulating vascular endothelial growth factor and soluble vascular endothelial growth factor receptor 1 in breast cancer.
Banerjee S; Pancholi S; A'hern R; Ghazoui Z; Smith IE; Dowsett M; Martin LA
Clin Cancer Res; 2008 May; 14(9):2656-63. PubMed ID: 18451229
[TBL] [Abstract][Full Text] [Related]
9. Soluble receptors for vascular endothelial growth factor (sVEGFR1/sVEGFR2) in infantile hemangioma.
Przewratil P; Sitkiewicz A; Andrzejewska E
Growth Factors; 2010 Dec; 28(6):417-25. PubMed ID: 20854187
[TBL] [Abstract][Full Text] [Related]
10. Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth.
Ebos JM; Lee CR; Bogdanovic E; Alami J; Van Slyke P; Francia G; Xu P; Mutsaers AJ; Dumont DJ; Kerbel RS
Cancer Res; 2008 Jan; 68(2):521-9. PubMed ID: 18199548
[TBL] [Abstract][Full Text] [Related]
11. Functional significance of vascular endothelial growth factor and its receptor (receptor-1) in various lung cancer types.
Ilhan N; Ilhan N; Deveci F
Clin Biochem; 2004 Sep; 37(9):840-5. PubMed ID: 15329326
[TBL] [Abstract][Full Text] [Related]
12. Vascular endothelial growth factor and its soluble receptor in benign and malignant ovarian tumors.
Artini PG; Ruggiero M; Monteleone P; Carpi A; Cristello F; Cela V; Genazzani AR
Biomed Pharmacother; 2008; 62(6):373-7. PubMed ID: 18037256
[TBL] [Abstract][Full Text] [Related]
13. Vascular endothelial growth factor and its soluble receptor in patients with polycystic ovary syndrome undergoing IVF.
Artini PG; Ruggiero M; Parisen Toldin MR; Monteleone P; Monti M; Cela V; Genazzani AR
Hum Fertil (Camb); 2009 Mar; 12(1):40-4. PubMed ID: 19330612
[TBL] [Abstract][Full Text] [Related]
14. Circulating vascular endothelial growth factor and its soluble receptors in patients with liver cirrhosis: possible association with hepatic function impairment.
Jaroszewicz J; Januszkiewicz M; Flisiak R; Rogalska M; Kalinowska A; Wierzbicka I
Cytokine; 2008 Oct; 44(1):14-7. PubMed ID: 18656381
[TBL] [Abstract][Full Text] [Related]
15. Clinical usefulness of assessing VEGF and soluble receptors sVEGFR-1 and sVEGFR-2 in women with breast cancer.
Thielemann A; Baszczuk A; Kopczyński Z; Kopczyński P; Grodecka-Gazdecka S
Ann Agric Environ Med; 2013; 20(2):293-7. PubMed ID: 23772579
[TBL] [Abstract][Full Text] [Related]
16. Plasma levels of soluble vascular endothelial growth factor receptor-1 may determine the onset of early and late ovarian hyperstimulation syndrome.
Pau E; Alonso-Muriel I; Gómez R; Novella E; Ruiz A; García-Velasco JA; Simón C; Pellicer A
Hum Reprod; 2006 Jun; 21(6):1453-60. PubMed ID: 16488907
[TBL] [Abstract][Full Text] [Related]
17. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award.
Chaiworapongsa T; Romero R; Espinoza J; Bujold E; Mee Kim Y; Gonçalves LF; Gomez R; Edwin S
Am J Obstet Gynecol; 2004 Jun; 190(6):1541-7; discussion 1547-50. PubMed ID: 15284729
[TBL] [Abstract][Full Text] [Related]
18. Role of soluble vascular endothelial growth factor receptor-1 in the vitreous in proliferative diabetic retinopathy.
Matsunaga N; Chikaraishi Y; Izuta H; Ogata N; Shimazawa M; Matsumura M; Hara H
Ophthalmology; 2008 Nov; 115(11):1916-22. PubMed ID: 18718666
[TBL] [Abstract][Full Text] [Related]
19. Signs of reduced angiogenic activity after surgical removal of deeply infiltrating endometriosis.
Bourlev V; Iljasova N; Adamyan L; Larsson A; Olovsson M
Fertil Steril; 2010 Jun; 94(1):52-7. PubMed ID: 19324337
[TBL] [Abstract][Full Text] [Related]
20. Soluble vascular endothelial growth factor receptor-1 (sVEGFR-1) is decreased in lung cancer patients showing progression: a pilot study.
Yilmaztepe A; Ulukaya E; Zik B; Yagci A; Sevimli A; Yilmaz M; Erdogan BB; Koc M; Akgoz S; Karadag M; Tokullugil A
Cancer Invest; 2007 Aug; 25(5):322-7. PubMed ID: 17661207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
